C
Crescendo Biologics (Formerly Translocus)
Novel T-cell enhancing Humabody® therapeutics for immuno-oncology
About Crescendo Biologics (Formerly Translocus)
Crescendo Biologics is a private, clinical-stage immuno-oncology company located in Cambridge, UK, that develops targeted T-cell enhancing therapeutics. Founded in 2007 and spun out of the Babraham Institute in 2009, the company leverages its proprietary, patent-protected transgenic mouse platform to generate fully human VH domain building blocks, known as Humabody® VH. This platform produces small, robust, and stable antibody fragments that can be configured into multi-functional therapeutics, offering superior tissue penetration and bio-distribution compared to conventional antibodies.
The company's business model revolves around advancing its proprietary pipeline and forming strategic collaborations with major pharmaceutical companies. Its revenue is generated through upfront payments, equity investments, research funding, and milestone payments from these partnerships, as well as future royalties on commercialized products. Crescendo has established significant multi-target discovery and development collaborations. A 2016 deal with Takeda focuses on developing Humabody®-based therapeutics for cancer, a partnership that was later expanded. In 2022, a collaboration was initiated with BioNTech to develop multi-specific precision immunotherapies, including mRNA-based antibodies and engineered cell therapies. Additionally, a 2018 worldwide licensing agreement with Zai Lab is centered on developing and commercializing ZL-1102 (formerly CB001), a topical Humabody® for inflammatory conditions like psoriasis, which has entered a global Phase 2 trial as of June 2024.
Crescendo's proprietary pipeline is led by CB307, a half-life extended CD137 x PSMA bispecific Humabody®. This candidate is designed to selectively activate tumor-specific T-cells within the tumor microenvironment, aiming for a durable anti-cancer effect while minimizing systemic toxicity. The clinical program for CB307 is underway in patients with PSMA-positive solid tumors (NCT04839991), with the first US patients dosed in late 2023. Other pipeline candidates include CB693, a CD137 x MSLN Humabody®, and CB213, a preclinical PD-1 x LAG-3 multi-specific Humabody.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 10
- Open positions
- None listed
- Dealroom signal
- 71.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Intellectual Property, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, proteomics, DT and LS, uk is8 life sciences, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Jul 2023 | $32M | $314M | Kreos Capital · IP Group · Andera Partners · Quan Capital | ↗ |
| LATE VCOther financing | Jan 2022 | $30M | $314M | BioNTech | ↗ |
Growth signals
Latest recorded traffic for Crescendo Biologics (Formerly Translocus) is 800 monthly website visits, down 27.3% over the last three months. Crescendo Biologics (Formerly Translocus)'s team declined 9.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Crescendo Biologics (Formerly Translocus) in the Cambridge ecosystem
The Crescendo Biologics (Formerly Translocus) office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Sofinnova Partners
UK Innovation & Science Seed Fund
Series A6 investors entered at this stage
Future Planet Capital
Imperial Innovations
Astellas Venture
EMBL Ventures
Andera Partners
Takeda Ventures
Series B and later4 investors entered at this stage
BioNTech
Kreos Capital
IP Group
Quan Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Crescendo Biologics (Formerly Translocus) on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Crescendo Biologics (Formerly Translocus)’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









